Fig. 1

Development of tumor mass and course of therapy of patients with anaplastic thyroid cancer who received lenvatinib and pembrolizumab as first-line therapy. A Spider-plot of change in total tumor mass after initiation of combination therapy with lenvatinib and pembrolizumab. Tumor size was determined by the sum of diameters of target-lesions. B Time on therapies for patients initially receiving lenvatinib and pembrolizumab. L + P: lenvatinib and pembrolizumab, L mono: lenvatinib monotherapy, P mono: pembrolizumab monotherapy